Cargando…

GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) significantly reduce postprandial blood glucose, inhibit appetite, and delay gastrointestinal emptying. However, it is controversial that some patients are intolerant to GLP-1RAs. METHODS: PubMed, Embase, Web of Science, and Cochrane L...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ziqi, Zhang, Qiling, Tan, Ying, Chen, Yu, Zhou, Xiqiao, Liu, Su, Yu, Jiangyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359616/
https://www.ncbi.nlm.nih.gov/pubmed/37484944
http://dx.doi.org/10.3389/fendo.2023.1149328
_version_ 1785075924154187776
author Zhang, Ziqi
Zhang, Qiling
Tan, Ying
Chen, Yu
Zhou, Xiqiao
Liu, Su
Yu, Jiangyi
author_facet Zhang, Ziqi
Zhang, Qiling
Tan, Ying
Chen, Yu
Zhou, Xiqiao
Liu, Su
Yu, Jiangyi
author_sort Zhang, Ziqi
collection PubMed
description BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) significantly reduce postprandial blood glucose, inhibit appetite, and delay gastrointestinal emptying. However, it is controversial that some patients are intolerant to GLP-1RAs. METHODS: PubMed, Embase, Web of Science, and Cochrane Library were searched for randomized controlled trials (RCTs) using GLP-1RAs with documented withdrawal due to gastrointestinal adverse reactions (GI AEs) from their inception to September 28, 2022. After extracting the information incorporated into the studies, a random-effects network meta-analysis was performed within a frequentist framework. RESULTS: 64 RCTs were finally enrolled, which included six major categories of the GLP-1RA. The sample size of the GLP-1RAs treatment group was 16,783 cases. The risk of intolerable gastrointestinal adverse reactions of Liraglutide and Semaglutide was higher than that of Dulaglutide. Meanwhile, the higher the dose of the same GLP-1RA preparation, the more likely to cause these adverse reactions. These intolerable GI AEs were not significantly related to drug homology or formulations and may be related to the degree of suppression of the appetite center. CONCLUSION: Dulaglutide caused the lowest intolerable GI AEs, while Liraglutide and Semaglutide were the highest. For Semaglutide, the higher the dose, the more likely it is to drive GI AEs. Meanwhile, the risk of these GI AEs is independent of the different formulations of the drug. All these findings can effectively guide individualized treatment. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022359346, identifier CRD42022359346.
format Online
Article
Text
id pubmed-10359616
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103596162023-07-22 GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis Zhang, Ziqi Zhang, Qiling Tan, Ying Chen, Yu Zhou, Xiqiao Liu, Su Yu, Jiangyi Front Endocrinol (Lausanne) Endocrinology BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) significantly reduce postprandial blood glucose, inhibit appetite, and delay gastrointestinal emptying. However, it is controversial that some patients are intolerant to GLP-1RAs. METHODS: PubMed, Embase, Web of Science, and Cochrane Library were searched for randomized controlled trials (RCTs) using GLP-1RAs with documented withdrawal due to gastrointestinal adverse reactions (GI AEs) from their inception to September 28, 2022. After extracting the information incorporated into the studies, a random-effects network meta-analysis was performed within a frequentist framework. RESULTS: 64 RCTs were finally enrolled, which included six major categories of the GLP-1RA. The sample size of the GLP-1RAs treatment group was 16,783 cases. The risk of intolerable gastrointestinal adverse reactions of Liraglutide and Semaglutide was higher than that of Dulaglutide. Meanwhile, the higher the dose of the same GLP-1RA preparation, the more likely to cause these adverse reactions. These intolerable GI AEs were not significantly related to drug homology or formulations and may be related to the degree of suppression of the appetite center. CONCLUSION: Dulaglutide caused the lowest intolerable GI AEs, while Liraglutide and Semaglutide were the highest. For Semaglutide, the higher the dose, the more likely it is to drive GI AEs. Meanwhile, the risk of these GI AEs is independent of the different formulations of the drug. All these findings can effectively guide individualized treatment. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022359346, identifier CRD42022359346. Frontiers Media S.A. 2023-07-06 /pmc/articles/PMC10359616/ /pubmed/37484944 http://dx.doi.org/10.3389/fendo.2023.1149328 Text en Copyright © 2023 Zhang, Zhang, Tan, Chen, Zhou, Liu and Yu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Zhang, Ziqi
Zhang, Qiling
Tan, Ying
Chen, Yu
Zhou, Xiqiao
Liu, Su
Yu, Jiangyi
GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
title GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
title_full GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
title_fullStr GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
title_full_unstemmed GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
title_short GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
title_sort glp-1ras caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359616/
https://www.ncbi.nlm.nih.gov/pubmed/37484944
http://dx.doi.org/10.3389/fendo.2023.1149328
work_keys_str_mv AT zhangziqi glp1rascausedgastrointestinaladversereactionsofdrugwithdrawalasystemreviewandnetworkmetaanalysis
AT zhangqiling glp1rascausedgastrointestinaladversereactionsofdrugwithdrawalasystemreviewandnetworkmetaanalysis
AT tanying glp1rascausedgastrointestinaladversereactionsofdrugwithdrawalasystemreviewandnetworkmetaanalysis
AT chenyu glp1rascausedgastrointestinaladversereactionsofdrugwithdrawalasystemreviewandnetworkmetaanalysis
AT zhouxiqiao glp1rascausedgastrointestinaladversereactionsofdrugwithdrawalasystemreviewandnetworkmetaanalysis
AT liusu glp1rascausedgastrointestinaladversereactionsofdrugwithdrawalasystemreviewandnetworkmetaanalysis
AT yujiangyi glp1rascausedgastrointestinaladversereactionsofdrugwithdrawalasystemreviewandnetworkmetaanalysis